Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral rating on Viatris, citing improving fundamentals, strong free cash flow, and undemanding valuations.